

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

1-44. (canceled)

45. (new) A composition for treating a pelvic inflammatory condition, comprising a sulfated proteoglycan and at least one ingredient selected from the group consisting of a sulfated hexosamine, a flavonoid, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, a CRH antagonist, caffeine, folic acid, a polyunsaturated fatty acid, and a polyamine.
46. (new) The composition of claim 45, wherein the proteoglycan is chondroitin sulfate, keratan sulfate, dermatan sulfate, or sodium hyaluronate.
47. (new) The composition of claim 46, wherein the proteoglycan is chondroitin sulfate.
48. (new) The composition of claim 45, wherein the flavonoid is quercetin, myricetin, genistein, or rutin.
49. (new) The composition of claim 45, further comprising olive kernel extract.
50. (new) The composition of claim 49, wherein the olive kernel extract is in the amount of 300-1,200 mg.
51. (new) The composition of claim 45, wherein the histamine-1 receptor antagonist is hydroxyzine, merelastine, azelastine, azatadine, or cyproheptadine.
52. (new) The composition of claim 47, wherein the sulfated hexosamine is D-glucosamine sulfate.
53. (new) The composition of claim 52, wherein the flavonoid is quercetin.
54. (new) The composition of claim 45, wherein the proteoglycan is in the amount of 10-3,000 mg, the sulfated hexosamine is in the amount of 10-3,000 mg, and the flavonoid is in the amount of 10-3,000 mg.
55. (new) The composition of claim 45, wherein the S-adenosylmethionine is in the amount of 3-1,000 mg.

56. (new) The composition of claim 45, wherein the proteoglycan is chondroitin sulfate, the flavonoid is quercetin, and the histamine-1 receptor antagonist is hydroxyzine.
57. (new) The composition of claim 56, wherein the chondroitin sulfate is in the amount of 50-300 mg, the quercetin is in the amount of 50-300 mg, and the hydroxyzine is in the amount of 50-300 mg.
58. (new) The composition of claim 45, wherein the proteoglycan is chondroitin sulfate, the flavonoid is myricetin, and the histamine-1 receptor antagonist is hydroxyzine.
59. (new) The composition of claim 58, wherein the chondroitin sulfate is in the amount of 50-300 mg, the myricetin is in the amount of 50-300 mg, and the hydroxyzine is in the amount of 50-300 mg.
60. (new) A method of treating a pelvic inflammatory condition, comprising administering an effective amount of the composition of claim 45 to a subject in need thereof.
61. (new) A method of treating a pelvic inflammatory condition, comprising administering an effective amount of the composition of claim 53 to a subject in need thereof.
62. (new) A method of treating a pelvic inflammatory condition, comprising administering an effective amount of the composition of claim 56 to a subject in need thereof.
63. (new) A method of treating a pelvic inflammatory condition, comprising administering an effective amount of the composition of claim 58 to a subject in need thereof.